Towards an understanding of barriers to condom use in rural Benin using the Health Belief Model: A cross sectional survey

Hounton, Sennen H.; Carabin, Hélène; Henderson, Neil J.
January 2005
BMC Public Health;2005, Vol. 5, p8
Academic Journal
Background: HIV/AIDS is the most dramatic epidemic of the century that has claimed over two decade more than 3 million deaths. Sub Saharan Africa is heavily affected and accounts for nearly 70% of all cases. Despite awareness campaigns, prevention measures and more recently promotion of anti viral regimens, the prevalence of cases and deaths is still rising and the prevalence of systematic condom use remains low, especially in rural areas. This study identifies barriers to condom use based on the Health Belief Model (HBM) in Benin, West Africa. Methods: The study was a cross-sectional survey conducted from June to July 2002. Two hundred fifty one (251) individuals were interviewed using a structured questionnaire adapted from a standardized WHO/GAP questionnaire. A logistic regression was used to identify factors associated with condom use. Results: In spite of satisfactory knowledge on HIV/AIDS transmission, participants are still at high risk of contracting the infection. Sixty three (63) percents of the interviewees reported being able to recognize infected people, and condom use during the last occasional intercourse was declared by only 36.8% of males and 47.5% of females. Based on the HBM, failure to use condom was related to its perceived lack of efficacy [OR = 9.76 (3.71-30.0)] and perceived quality [OR = 3.61 (1.31-9.91)]. Conclusions: This study identifies perceived efficacy (incomplete protective effect) and perceived utilization-related problem (any reported problem using condoms) as the main barriers to condom use. Hence, preventions strategies based on increasing perceived risk, perceived severity or adequate knowledge about HIV/AIDS may not be sufficient to induce condom use. These data will be useful in designing and improving HIV/AIDS prevention outreach programs in Sub Saharan Africa.


Related Articles

  • 'Chemical condom' tantalisingly close. Wilson, Clare // New Scientist;4/10/2004, Vol. 182 Issue 2442, p12 

    Creams that block HIV infection during sex have now become a major focus of AIDS research. Prevention campaigns focus on condoms, but not everyone is happy to use them and many women, especially in developing countries, cannot insist that their partners wear condoms. Hence the interest in...

  • Next trial for Starpharma.  // Australian Life Scientist;8/13/2008, p1 

    Starpharma studies VivaGel duration

  • HIV-associated nephropathy: a diagnosis in evolution. Ray, Patricio E. // Nephrology Dialysis Transplantation;Nov2012, Vol. 27 Issue 11, p3969 

    HIV-1 associated nephropathy (HIVAN) is a clinical and renal histological disease characterized by the presence of heavy proteinuria associated with focal segmental glomerulosclerosis and microcystic tubular dilatation. These renal lesions lead to renal enlargement and rapid progression to...

  • Causes of the decline in AIDS deaths, United States, 1995–2002: prevention, treatment or both? Holtgrave, David R. // International Journal of STD & AIDS;Dec2005, Vol. 16 Issue 12, p777 

    The decline in AIDS deaths in the USA between 1995 and 2002 has been attributed by Centers for Disease Control (CDC) to HIV treatments advances. The purpose of the present study is to assess whether this AIDS deaths decline was due entirely to treatment advances, to earlier prevention successes,...

  • Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model. Page, Mark; Stebbings, Richard; Berry, Neil; Hull, Robin; Ferguson, Deborah; Davis, Leanne; Duffy, Laura; Elsley, William; Hall, Joanna; Ham, Claire; Hassall, Mark; Bo Li; Mee, Edward T.; Quartey-Papafio, Ruby; Rose, Nicola J.; Mathy, Nathalie; Voss, Gerald; Stott, E. James; Almond, Neil // Retrovirology;2012, Vol. 9 Issue 1, p56 

    Background: Current data suggest that an efficacious human immunodeficiency virus type 1 (HIV-1) vaccine should elicit both adaptive humoral and cell mediated immune responses. Such a vaccine will also need to protect against infection from a range of heterologous viral variants. Here we have...

  • Measuring Coverage in MNCH: Population HIV-Free Survival among Children under Two Years of Age in Four African Countries Stringer, Jeffrey S. A.; Stinson, Kathryn; Tih, Pius M.; Giganti, Mark J.; Ekouevi, Didier K.; Creek, Tracy L.; Welty, Thomas K.; Chi, Benjamin H.; Wilfert, Catherine M.; Shaffer, Nathan; Stringer, Elizabeth M.; Dabis, Francois; Coetzee, David // PLoS Medicine;May2013, Vol. 10 Issue 5, p1 

    Background: Population-based evaluations of programs for prevention of mother-to-child HIV transmission (PMTCT) are scarce. We measured PMTCT service coverage, regimen use, and HIV-free survival among children ≤24 mo of age in Cameroon, Côte D'Ivoire, South Africa, and Zambia. ...

  • Preventive Antiretroviral Use Expands: Approved for HIV Exposure Outside of Work Settings. Voelker, Rebecca // JAMA: Journal of the American Medical Association;3/9/2005, Vol. 293 Issue 10, p1177 

    Reports on the expansion of the use of antiretroviral drugs to prevent HIV infection following nonoccupational exposure to the virus. How sufficient evidence exists for the United States to sanction antiretrovirals to be used in such a manner; Caution of experts about their use; Guidelines for...

  • Early Experiences Implementing Pre-exposure Prophylaxis (PrEP) for HIV Prevention in San Francisco. Liu, Albert; Cohen, Stephanie; Follansbee, Stephen; Cohan, Deborah; Weber, Shannon; Sachdev, Darpun; Buchbinder, Susan // PLoS Medicine;Mar2014, Vol. 11 Issue 3, p1 

    : Albert Liu and colleagues report early experiences with uptake and delivery of pre-exposure prophylaxis(PrEP)for HIV prevention in three different settings in San Francisco. PrEP can be an important component of a comprehensive HIV prevention program and can complement efforts to increase HIV...

  • HIV Treatment as Prevention: Considerations in the Design, Conduct, and Analysis of Cluster Randomized Controlled Trials of Combination HIV Prevention Boily, Marie-Claude; Mâsse, Benoît; Alsallaq, Ramzi; Padian, Nancy S.; Eaton, Jeffrey W.; Vesga, Juan F.; Hallett, Timothy B. // PLoS Clinical Trials;Jul2012, Vol. 7 Issue 7, p1 

    The rigorous evaluation of the impact of combination HIV prevention packages at the population level will be critical for the future of HIV prevention. In this review, we discuss important considerations for the design and interpretation of cluster randomized controlled trials (C-RCTs) of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics